Last Updated: November 20, 2026

Details for Patent: 4,058,552

« Back to Dashboard


Summary for Patent: 4,058,552
Title:Esters of p-carbonylphenoxy-isobutyric acids
Abstract:This invention is concerned with esters of p-carbonylphenoxy-isobutyric acids of the general formulae: (I) and (Ia) WHEREIN R is a phenyl group substituted by one or two halogen atoms; R' is H, CH3, C6H5, SCH3, OCH3, or, SO2CH3; R'' is CH3 or C2H5; Y is C1-C4 alkoxy, phenoxy, phenoxy substituted by one or two halogen atoms, or, OCH2O-CO-C(CH3)3; Z is C1-C4 alkyl, phenyl or R; NR1R2 is N(CH3)2N(C2H5)2, morpholino, piperidino, azepino, pyrrolidino.
Inventor(s):Andre Mieville
Assignee: Orchimed SA
Application Number:US05/600,127
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;
Patent landscape, scope, and claims:

# United States Patent 4,058,552: Fenofibrate Claim Scope, Expiration, and Patent Landscape

U.S. Patent No. 4,058,552 covers a genus of substituted esters of p-carbonylphenoxy-isobutyric acid, including fenofibrate as the expressly claimed compound in claim 5. The patent issued on November 15, 1977, and its original 17-year U.S. patent term expired in 1994. It no longer creates an enforceable barrier to manufacture, sale, or use of fenofibrate in the United States. Current commercial protection has historically focused on micronized formulations, dissolution-enhanced compositions, dosage forms, and fenofibric-acid products rather than the expired active-ingredient patent. [1]

What drug does U.S. Patent 4,058,552 protect?

The patent protects a class of lipid-lowering compounds related to fenofibrate. Claim 5 identifies the key commercial molecule:

Isopropyl p-(4-chlorobenzoyl)phenoxy-isobutyrate.

That compound is fenofibrate, chemically known as isopropyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate.

Fenofibrate is a prodrug that is hydrolyzed primarily to fenofibric acid. It is used with diet and other measures to treat dyslipidemia, including hypertriglyceridemia and mixed dyslipidemia. U.S. Food and Drug Administration labeling identifies fenofibrate as a peroxisome proliferator-activated receptor alpha agonist. [2]

The patent’s commercial significance arose from three elements:

  1. It claimed fenofibrate itself.
  2. It claimed related structural analogues through Markush language.
  3. It claimed pharmaceutical compositions containing the compounds for reducing blood cholesterol and lipids.

What are the principal claims in U.S. Patent 4,058,552?

Claim 1: broad chemical genus

Claim 1 covers esters of p-carbonylphenoxy-isobutyric acid having a substituted aromatic group and variable substituents represented by R, R', R", and Y.

The relevant limitations are:

Variable Claimed alternatives
R Phenyl substituted by one or two halogen atoms
R' H, methyl, phenyl, methylthio, methoxy, or methylsulfonyl
R" Methyl or ethyl
Y C1-C4 alkoxy, phenoxy, halogen-substituted phenoxy, or a tert-butylcarbonyl-substituted methylenedioxy group

This is a Markush claim. It does not protect every lipid-lowering compound or every phenoxyisobutyric acid derivative. It protects compounds that satisfy the claimed structural variables and the connectivity shown in the patent’s chemical formula.

The claim has two important boundaries:

  • The aromatic R group must be halogen-substituted.
  • The ester and substituent positions must match the structural formula incorporated into the claim.

Because the structural formula supplied in the question is represented only by an image placeholder, the textual variables alone do not establish every atom-to-atom relationship. The definitive scope depends on the formula printed in the issued patent.

Claim 2: narrower subgenus

Claim 2 narrows R to four chlorophenyl arrangements:

  • 4-chlorophenyl;
  • 3-chlorophenyl;
  • 3,4-dichlorophenyl; and
  • 2,6-dichlorophenyl.

It narrows Y to:

  • methoxy;
  • ethoxy; and
  • isopropoxy.

Claim 2 therefore removes several alternatives from claim 1 and concentrates protection on chlorinated aromatic compounds with simple alkoxy groups.

Claims 3 and 4: aromatic-substitution subclasses

Claim 3 covers compounds in which R is 4-chlorophenyl.

Claim 4 covers compounds in which R is 3,4-dichlorophenyl.

These claims are narrower than claim 1 but do not, on their face, limit the complete compound to fenofibrate. Their scope remains subject to the other variables and the structural formula of claim 1.

Claim 5: fenofibrate

Claim 5 is the strongest commercial claim because it specifically names the fenofibrate structure:

Isopropyl p-(4-chlorobenzoyl)phenoxy-isobutyrate.

This claim is narrower than the genus claims but provides a direct species claim to the principal marketed active ingredient.

Claim 6: therapeutic composition

Claim 6 covers a pharmaceutical composition containing:

  • a compound within claim 1; and
  • a pharmaceutically acceptable excipient;

in a therapeutically effective amount for reducing blood cholesterol and lipid content.

Claim 6 is a composition claim, not a conventional method-of-treatment claim. It does not expressly recite a particular tablet, capsule, particle-size distribution, dissolution profile, surfactant, or manufacturing process.

When did U.S. Patent 4,058,552 expire?

U.S. Patent 4,058,552 issued on November 15, 1977. For a patent of that vintage, the ordinary U.S. term was 17 years from issuance. On that basis, the patent expired on November 15, 1994. [1]

Event Date
U.S. patent issuance November 15, 1977
Ordinary patent term 17 years from issuance
Expiration November 15, 1994
Current enforceability None

The patent predates the patent-term rules that generally calculate term from the earliest effective nonprovisional filing date. Patent-term adjustment and patent-term extension were not relevant in the modern sense to this original compound patent.

The expiration eliminated exclusivity in the active ingredient. It did not automatically invalidate later patents covering formulations, dosage forms, manufacturing processes, or alternative active ingredients.

What compounds fall within the patent’s claim scope?

The patent’s claim structure reaches compounds with the following combination:

  1. A p-carbonylphenoxy-isobutyric acid ester core.
  2. A halogenated phenyl group.
  3. One of the claimed R' substituents.
  4. A methyl or ethyl R" group.
  5. One of the claimed Y substituents.

Fenofibrate is the most commercially important example because it uses:

  • a 4-chlorophenyl group;
  • an isopropyl ester;
  • the 4-chlorobenzoyl-substituted phenoxy-isobutyric acid framework.

The scope does not necessarily cover:

  • fenofibric acid itself, because fenofibric acid is the hydrolyzed acid rather than the claimed isopropyl ester;
  • unrelated fibrates such as gemfibrozil, bezafibrate, ciprofibrate, or clofibrate;
  • salts or polymorphs unless they fall within the recited ester structure;
  • formulations that do not contain a compound within claim 1.

A product containing fenofibrate would have fallen within claim 5 during the patent term. A product containing a different fibrate would require a separate claim chart against the genus limitations.

What is the Orange Book status of the patent?

U.S. Patent 4,058,552 is not a current enforceable Orange Book barrier. Its claims expired decades ago.

The FDA Orange Book lists patents associated with approved drug products, but listing does not extend an expired patent’s term. Orange Book relevance depends on the approved product, the applicable NDA, the patent’s expiration date, and whether the patent is still eligible for listing. [3]

For fenofibrate products, later Orange Book-listed patents historically addressed pharmaceutical compositions and delivery characteristics, including formulation approaches designed to improve the dissolution and bioavailability of the poorly water-soluble active ingredient. Those patents were commercially more relevant to ANDA litigation than the expired 4,058,552 compound patent.

The patent should therefore be classified as:

Orange Book issue Assessment
Active-ingredient protection Expired
Current blocking right None
Historical Paragraph IV relevance High during the 1980s and early 1990s
Current generic barrier None from this patent
Formulation patent relevance Separate analysis required

What formulation patents protected fenofibrate products?

Fenofibrate has low aqueous solubility. Later product development focused on improving dissolution and absorption through particle-size reduction, micronization, excipients, wetting agents, and formulation design.

Historically important fenofibrate formulation patents included patents associated with:

  • micronized fenofibrate;
  • fenofibrate combined with surfactants or hydrophilic excipients;
  • dissolution-enhanced oral dosage forms;
  • tablets and capsules containing controlled particle-size material;
  • formulations designed to reduce dependence on administration with a high-fat meal.

A frequently cited later patent is U.S. Patent No. 6,074,670, which concerned pharmaceutical compositions containing fenofibrate and was associated with later commercial formulation protection. [4] The legal scope of that patent was materially different from U.S. Patent 4,058,552 because it focused on composition and performance characteristics rather than claiming the original fenofibrate molecule as a chemical species.

Fenofibrate formulation patents generally presented narrower but commercially practical claim strategies. A generic manufacturer could avoid a composition patent by using a different excipient system, particle-size profile, manufacturing process, or dosage form, provided the alternative did not satisfy the asserted claims.

What method-of-use patents cover fenofibrate?

U.S. Patent 4,058,552 does not appear, from the claims provided, to contain a conventional method-of-treatment claim such as administering fenofibrate to a patient to treat a specified disease.

Claim 6 is directed to a composition. Its therapeutic purpose helps define the claimed composition, but the claim does not expressly require:

  • a particular patient population;
  • a dosage regimen;
  • a triglyceride threshold;
  • a cardiovascular-risk reduction outcome;
  • combination therapy with a statin;
  • treatment of a specific dyslipidemia subtype.

Later fenofibrate patents and regulatory exclusivities could address different clinical uses, formulations, or combinations. Those rights would need to be analyzed independently from the expired compound patent.

Which companies challenged fenofibrate patents?

Fenofibrate generated generic competition through ANDA filings after expiration of the original active-ingredient patent. Generic manufacturers and applicants included companies such as:

  • Teva Pharmaceuticals;
  • Mylan;
  • Sandoz;
  • Apotex;
  • Dr. Reddy’s Laboratories;
  • Lupin;
  • Impax and related U.S. generic applicants.

The precise litigants varied by product, dosage strength, formulation, and NDA. Litigation often centered on later formulation patents rather than U.S. Patent 4,058,552.

Typical ANDA certifications included:

  • Paragraph I, where no relevant patent was listed;
  • Paragraph II, where the listed patent had expired;
  • Paragraph III, where the applicant accepted delayed entry until expiration;
  • Paragraph IV, alleging that a listed patent was invalid, unenforceable, or not infringed.

Once the original compound patent expired in 1994, Paragraph IV disputes shifted toward formulation patents and product-specific Orange Book listings. Under the Hatch-Waxman framework, a Paragraph IV notice could trigger patent litigation and a 30-month stay of FDA approval for the affected ANDA, subject to the statutory requirements. [5]

How strong is the patent estate for fenofibrate?

The original chemical patent was strong during its term because claim 5 directly covered fenofibrate and claim 1 potentially reached a broader group of related compounds. Its current strength is zero because it is expired.

The historical estate can be assessed as follows:

Estate component Historical strength Current status
Fenofibrate molecule High; direct species claim Expired
Broad chemical genus Potentially broad but subject to claim construction and validity limits Expired
General lipid-lowering composition Moderate; dependent on claim interpretation Expired
Micronized formulation Product-specific and commercially significant Patent-specific; many historical rights expired
Bioavailability-enhanced formulation Potentially strong if narrowly claimed and supported by data Patent-specific
Fenofibric acid products Separate active ingredient and patent estate Separate analysis
Manufacturing process Depends on process claims and trade-secret controls Separate analysis

The principal weakness of relying on the 4,058,552 patent today is expiration. The principal historical strength was the direct recitation of fenofibrate in claim 5.

What generic entry risks exist for fenofibrate?

Generic entry risk is high for products relying only on the fenofibrate active ingredient. The molecule is off patent, widely characterized, and available through multiple generic suppliers.

Residual risks historically arose from:

  • formulation patents;
  • particle-size specifications;
  • bioequivalence requirements;
  • food-effect differences;
  • manufacturing process claims;
  • patent litigation tied to a particular reference-listed drug;
  • regulatory exclusivity associated with a later product or indication.

A generic applicant using a formulation materially different from the branded product may reduce formulation-patent exposure but face separate FDA bioequivalence or clinical-performance requirements. For immediate-release oral fenofibrate products, the regulatory pathway is generally an ANDA where the applicant can demonstrate pharmaceutical equivalence and bioequivalence to the reference product. [3]

How does fenofibrate compare with other fibrates?

Drug Active ingredient Relationship to U.S. 4,058,552 Current competitive position
Fenofibrate Isopropyl ester of fenofibric acid Expressly claimed in claim 5 Multiple generic products
Fenofibric acid Active acid metabolite Not the same ester species Separate products and patent history
Gemfibrozil Distinct substituted phenoxy acid Not covered by the identified fenofibrate species claim Generic
Bezafibrate Distinct benzamide fibrate Not covered by claim 5 Used mainly outside the U.S.
Ciprofibrate Distinct chlorophenoxy isobutyric acid derivative Requires separate claim analysis Used in selected markets
Clofibrate Older fibrate ester Structurally distinct Limited current use

Fenofibrate’s commercial differentiation historically depended less on the original molecule and more on formulation performance, dosing convenience, triglyceride efficacy, and coadministration with statins.

What licensing and commercial rights affected fenofibrate?

The patent was associated with the original European pharmaceutical development of fenofibrate and later commercialization by companies including Fournier and Abbott Laboratories. Abbott acquired Fournier-related assets and marketed Tricor in the United States. AbbVie later became the relevant successor company for Abbott’s pharmaceutical business.

The commercial rights should be separated into:

  • original compound patent rights;
  • national patent-family rights;
  • product and trademark rights;
  • formulation patent rights;
  • regulatory rights under specific NDAs;
  • manufacturing and supply agreements.

Expiration of U.S. Patent 4,058,552 did not terminate trademarks such as Tricor, nor did it eliminate proprietary know-how relating to particle engineering, manufacturing controls, or formulation scale-up.

What litigation status applies to U.S. Patent 4,058,552?

No current infringement litigation can be based on an expired patent for prospective commercial activity. Any historical litigation involving this patent would have concerned activity during its enforceable term and could have included validity, infringement, inventorship, patent-term, or regulatory-entry issues.

Later fenofibrate litigation generally involved:

  • formulation patents;
  • ANDA Paragraph IV certifications;
  • infringement under 35 U.S.C. § 271(e)(2);
  • obviousness and written-description defenses;
  • claim construction concerning excipient quantities and dissolution performance;
  • settlement agreements establishing generic launch dates.

A historical settlement involving a later formulation patent would not revive or extend the term of U.S. Patent 4,058,552.

Key Takeaways

  • U.S. Patent 4,058,552 claims a genus of substituted p-carbonylphenoxy-isobutyric acid esters.
  • Claim 5 expressly covers fenofibrate.
  • Claim 6 covers pharmaceutical compositions containing a claim 1 compound with a pharmaceutically acceptable excipient.
  • The patent issued November 15, 1977, and expired November 15, 1994.
  • It provides no current enforceable exclusivity in the United States.
  • Fenofibrate’s later patent landscape focused on micronized and dissolution-enhanced formulations, not the expired active-ingredient claim.
  • Generic-entry risk is high for products that do not practice unexpired formulation or process claims.
  • Orange Book and ANDA analysis must be conducted by reference-listed drug and dosage form because later formulation patents varied by product.

FAQs

Does U.S. Patent 4,058,552 cover fenofibric acid?

No. The patent expressly claims fenofibrate in claim 5, which is an isopropyl ester. Fenofibric acid is the corresponding hydrolyzed acid and requires separate claim coverage.

Can a company manufacture fenofibrate without a license today?

Yes, U.S. Patent 4,058,552 expired in 1994. A manufacturer must still address other enforceable patents, FDA requirements, trademarks, and applicable regulatory obligations.

Is fenofibrate still protected by patents?

The original fenofibrate molecule is no longer protected by the ’552 patent. Product-specific formulation, dosage-form, process, or fenofibric-acid patents must be assessed separately.

Did claim 6 create a method-of-treatment patent?

No. Claim 6 is drafted as a pharmaceutical composition claim. It identifies a therapeutic purpose but does not recite a standalone patient-treatment method.

Does patent expiration eliminate FDA exclusivity?

No. Patent expiration and FDA regulatory exclusivity are separate legal regimes. A product can have no blocking patent and still be subject to a regulatory exclusivity period applicable to a particular NDA or indication.

References

  1. U.S. Patent and Trademark Office. (1977). U.S. Patent No. 4,058,552: Esters of p-carbonylphenoxy-isobutyric acid, process for preparing them and pharmaceutical compositions containing them.
  2. U.S. Food and Drug Administration. (2023). Fenofibrate prescribing information.
  3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations (Orange Book).
  4. U.S. Patent and Trademark Office. (2000). U.S. Patent No. 6,074,670: Pharmaceutical composition containing fenofibrate.
  5. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 4,058,552

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 4,058,552

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Switzerland1517/69Jan 31, 1969
Switzerland13022/69Aug 28, 1969

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.